GlassScriptPhysician profile
Rhonda Casto
NPI 1396148235
$10,168.05
in general payments reported to CMS, 2019-2025
29 companies · $572 in 2025
The $572 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,638 · 2022: $2,754 · 2023: $3,430 · 2024: $1,774 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,775.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,206.67 | 2022-2024 | Azstarys |
| Abbvie INC. | $1,147.36 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,099.52 | 2021-2025 | Caplyta |
| Neos Therapeutics, LP | $1,081.67 | 2021-2025 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $603.32 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $578.81 | 2021-2024 | Trintellix |
| Alkermes, INC. | $572.33 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $481.21 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lundbeck LLC | $441.81 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $441.73 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $411.51 | 2021-2024 | Ingrezza |
| Bausch Health US, LLC | $323.41 | 2022-2025 | Aplenzin |
| Noven Therapeutics, LLC | $293.02 | 2021-2024 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $249.80 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $172.17 | 2023-2025 | Loreev Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $164.40 | 2022-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $156.22 | 2021-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $152.64 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $130.60 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $128.24 | 2022-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $91.42 | 2021-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $76.09 | 2021 | |
| Eisai INC. | $66.81 | 2021-2022 | |
| Owp Pharmaceuticals, INC. | $21.28 | 2023 | Subvenite, Lamotrigine |
| Jazz Pharmaceuticals INC. | $18.99 | 2022 | |
| Noven Pharmaceuticals, INC. | $16.38 | 2024 | Xelstrym |
| Tempus Ai, INC | $15.47 | 2024 | |
| Acadia Pharmaceuticals INC | $14.54 | 2021 | |
| Aytu Biopharma, INC. | $10.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Casto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.